查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493521

學名藥市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、藥物輸送、形式、來源、配銷通路、地區和競爭細分，2019-2029F

Generic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Drug Delivery, By Form, By Source, By Distribution Channel, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球學名藥市場估值為 4,434.4 億美元，預計在預測期內將穩定成長，到 2029 年複合年成長率為 6.18%。的醫療費用以及對負擔得起的治療方案的需求。學名藥為品牌藥物提供了一種經濟有效的替代品，使更多人群能夠使用它們。品牌藥物的專利到期為學名藥製造商進入市場創造了機會，導致競爭加劇和價格下降。政府推廣使用學名藥以減少醫療保健支出的措施進一步推動了市場成長。新興市場對生物藥學名藥的需求不斷成長以及學名藥生產能力的擴大也有助於市場的擴張。在可負擔性、可近性和市場競爭的推動下，全球學名藥市場可望持續成長。

市場概況
預測期 2025-2029
2023 年市場規模 4434.4億美元
2029 年市場規模 6408.8億美元
2024-2029 年複合年成長率 6.18%
成長最快的細分市場 小分子學名藥
最大的市場 北美洲

主要市場促進因素

成本效益和負擔能力

專利到期和排他性喪失

政府政策與舉措

慢性病盛行率增加

主要市場挑戰

監管障礙和核准流程

智慧財產權和專利訴訟

主要市場趨勢

學名藥（生物相似藥）的進展

技術進步與製造創新

細分市場洞察

類型洞察

應用洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（小分子學名藥和生物學名藥）
    • 按應用（心血管疾病、糖尿病、神經病學、腫瘤學、抗發炎疾病、其他）
    • 透過藥物輸送（口服、局部、腸胃外、其他）
    • 按劑型（片劑、膠囊、注射劑、其他）
    • 按來源（內部和合約製造組織）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 透過藥物輸送
    • 按形式
    • 按來源
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 透過藥物輸送
    • 按形式
    • 按來源
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 透過藥物輸送
    • 按形式
    • 按來源
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 透過藥物輸送
    • 按形式
    • 按來源
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 透過藥物輸送
    • 按形式
    • 按來源
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最近的發展

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • STADA Arzneimittel AG
  • Aurobindo Pharma Limited
  • Dr Reddy's Laboratories Ltd.
  • Cipla Ltd.
  • Novo Nordisk A/S
  • Abbott Laboratories Inc.
  • Endo International plc
  • Sanofi SA
  • Aspen Pharmacare Holdings Limited
  • Lupin Limited

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 7332

Global Generic Drugs Market was valued at USD 443.44 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.18% through 2029. The Global Generic Drugs Market is primarily driven by several key factors, including the rising prevalence of chronic diseases, increasing healthcare costs, and the need for affordable treatment options. Generic drugs offer a cost-effective alternative to brand-name medications, making them accessible to a broader population. Patent expirations of branded drugs create opportunities for generic manufacturers to enter the market, leading to increased competition and lower prices. Government initiatives promoting the use of generic drugs to reduce healthcare expenditures further fuel market growth. The growing demand for generic versions of biologic drugs and the expansion of generic drug manufacturing capabilities in emerging markets also contribute to the market's expansion. The Global Generic Drugs Market is poised for sustained growth driven by affordability, accessibility, and market competition.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 443.44 Billion
Market Size 2029USD 640.88 Billion
CAGR 2024-20296.18%
Fastest Growing SegmentSmall Molecule Generics
Largest MarketNorth America

Key Market Drivers

Cost-effectiveness and Affordability

The affordability and accessibility of generic drugs compared to their brand-name counterparts constitute a pivotal factor driving their widespread adoption and market expansion on a global scale. Generic medications, renowned for their lower price points, serve as indispensable alternatives for patients and healthcare systems grappling with constrained budgets or exorbitant out-of-pocket expenses associated with branded pharmaceuticals. In regions where healthcare resources are scarce or where patients bear a substantial burden of medication costs, the cost-effectiveness of generic drugs emerges as a cornerstone of healthcare provision. The considerable price differentials between generic and brand-name medications facilitate broader access to essential treatments, ensuring that individuals can afford the medications they need to manage their health conditions effectively.

A fundamental driver of the cost-effectiveness of generic drugs lies in the expiration of patents on brand-name medications. Upon patent expiry, generic manufacturers gain the legal right to produce and distribute equivalent versions of the drug, igniting competition within the pharmaceutical market. This competitive landscape fosters price reductions as generic manufacturers leverage economies of scale, streamlined production processes, and reduced research and development costs to offer their products at significantly lower prices.

Patent Expirations and Loss of Exclusivity

The expiration of patents on branded drugs serves as a catalyst for the growth and evolution of the generic drugs market, heralding a transformative phase characterized by heightened competition, expanded consumer choice, and decreased medication costs. When patents on brand-name pharmaceuticals reach their expiration date, generic manufacturers gain the legal authorization to develop, produce, and market bioequivalent versions of these medications. This pivotal milestone liberates the formulation and production processes from the constraints of intellectual property rights, fostering an environment conducive to innovation, affordability, and accessibility within the pharmaceutical landscape.

The advent of generic alternatives following patent expiration precipitates a paradigm shift in market dynamics, instigating a surge in competition among pharmaceutical entities vying for market share. Generic manufacturers, armed with the freedom to replicate established formulations and therapeutic compositions, embark on rigorous development and manufacturing endeavors to create bioequivalent versions of branded drugs. By leveraging economies of scale, streamlined production processes, and strategic cost management techniques, generic manufacturers endeavor to offer their products at markedly lower price points, compelling incumbent brand-name companies to recalibrate their pricing strategies in response to the intensified competitive pressures.

Government Policies and Initiatives

The implementation of policies and initiatives by governments to encourage the utilization of generic drugs represents a strategic approach aimed at mitigating healthcare expenditure burdens while ensuring equitable access to essential medications. Recognizing the pivotal role that generic drugs play in fostering cost containment and enhancing healthcare affordability, governments worldwide institute a spectrum of measures tailored to promote the adoption and utilization of generic medications within healthcare systems.

One of the cornerstone policies embraced by governments is the enactment of generic substitution laws, which empower pharmacists to dispense generic equivalents of prescribed medications in lieu of their branded counterparts, provided they meet stringent bioequivalence and safety standards. By facilitating seamless substitution at the point of dispensation, these laws incentivize patients and healthcare providers to opt for cost-effective generic alternatives, thereby driving market growth and fostering competition within the pharmaceutical landscape.

Increasing Chronic Disease Prevalence

The escalating prevalence of chronic diseases constitutes a pervasive global health challenge, precipitating a surge in demand for sustained medication regimens aimed at managing these debilitating conditions. Chronic diseases, encompassing a diverse spectrum of ailments ranging from cardiovascular diseases and diabetes to cancer, impose a substantial burden on healthcare systems worldwide, necessitating comprehensive strategies to optimize disease management and enhance patient outcomes. Against this backdrop, generic drugs emerge as indispensable therapeutic modalities, offering cost-effective treatment options that cater to the burgeoning medication needs of individuals grappling with chronic illnesses.

The rising tide of chronic diseases underscores the imperative for long-term medication use, as patients afflicted with these conditions often require ongoing pharmacological interventions to mitigate symptoms, prevent disease progression, and improve quality of life. Generic drugs, characterized by their affordability and accessibility, assume a pivotal role in addressing the burgeoning medication needs of individuals afflicted with chronic diseases, ensuring equitable access to essential treatments irrespective of socioeconomic status or geographical location. By offering comparable efficacy and safety profiles to their brand-name counterparts at significantly lower price points, generic medications empower patients to adhere to prescribed treatment regimens, thereby mitigating disease complications and averting adverse health outcomes.

Key Market Challenges

Regulatory Hurdles and Approval Processes

One of the primary challenges confronting the Global Generic Drugs Market is navigating the complex regulatory landscape governing generic drug approval processes. Regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, enforce stringent standards and requirements for the approval of generic medications. Generic manufacturers must demonstrate bioequivalence, pharmaceutical equivalence, and therapeutic equivalence to the reference brand-name drug through comprehensive analytical and clinical studies. The regulatory pathway for generic drug approval often entails navigating intricate legal frameworks, conducting extensive pharmacokinetic and pharmacodynamic studies, and adhering to stringent quality assurance standards, all of which pose formidable barriers to entry for manufacturers. Disparities in regulatory requirements between different regions and countries necessitate meticulous compliance with diverse regulatory mandates, adding complexity and uncertainty to the generic drug approval process.

Intellectual Property Rights and Patent Litigation

Another significant challenge confronting the Global Generic Drugs Market is the intricate landscape of intellectual property rights and patent litigation surrounding branded pharmaceutical products. Brand-name drug manufacturers frequently employ patent protection strategies to safeguard their market exclusivity and deter generic competition. As a result, generic manufacturers may encounter patent barriers and legal challenges when seeking to develop and market generic equivalents of branded drugs. Patent litigation, infringement disputes, and settlement agreements between brand-name and generic manufacturers further complicate market entry for generics, potentially delaying market access and impeding competition. The intricate interplay between intellectual property rights, patent litigation, and regulatory approval processes underscores the formidable challenges faced by generic manufacturers in navigating the competitive landscape of the pharmaceutical industry.

Key Market Trends

Advancements in Generic Biologics (Biosimilars)

The emergence of biosimilars heralds a transformative paradigm shift within the pharmaceutical landscape, ushering in a new era of accessibility, affordability, and innovation in biologic drug therapy. Biosimilars, colloquially referred to as generic versions of biologic drugs, constitute a rapidly burgeoning segment of the generic drugs market, poised to revolutionize the treatment landscape across a diverse array of therapeutic domains. This paradigmatic evolution is underpinned by significant advancements in biotechnology and regulatory frameworks governing biosimilar approval, which collectively catalyze the development, commercialization, and widespread adoption of biosimilar therapies as compelling alternatives to their costly brand-name counterparts.

The ascendancy of biosimilars as a burgeoning force within the generic drugs market is predicated upon the intricate interplay between scientific innovation and regulatory harmonization. Pioneering breakthroughs in biotechnological methodologies have empowered manufacturers to elucidate the complex structural and functional attributes of biologic drugs with unparalleled precision and fidelity, thereby facilitating the rational design and engineering of biosimilar formulations that closely mimic the reference biologic products. Leveraging state-of-the-art analytical techniques, manufacturers can meticulously characterize the physicochemical properties, pharmacokinetic profiles, and immunogenicity profiles of biosimilars, ensuring their comparability to the reference biologic drugs with utmost rigor and scientific rigor.

Technological Advancements and Manufacturing Innovations

Technological advancements in drug formulation, manufacturing processes, and quality assurance represent a pivotal catalyst for innovation and progress within the realm of generic drug production, ushering in a transformative era characterized by enhanced efficiency, scalability, and quality assurance standards. Against the backdrop of a burgeoning global demand for cost-effective pharmaceutical solutions, these pioneering technological innovations serve as linchpins of competitiveness and sustainability within the generic drugs market, bolstering manufacturing capabilities, streamlining production workflows, and fortifying product quality and consistency with unparalleled precision and efficacy.

At the forefront of these technological advancements lies the advent of continuous manufacturing methodologies, a groundbreaking paradigm shift that revolutionizes traditional batch-based manufacturing processes. Continuous manufacturing confers unparalleled advantages in terms of process efficiency, enabling manufacturers to seamlessly integrate unit operations and manufacturing steps within a continuous, uninterrupted production line. By obviating the need for discrete batch processing and affording real-time monitoring and control capabilities, continuous manufacturing optimizes resource utilization, reduces manufacturing cycle times, and enhances product quality attributes, culminating in cost savings and operational efficiencies that underpin the competitiveness of the generic drugs market.

Segmental Insights

Type Insights

Based on the type, small molecule generics have traditionally emerged as the fastest growing segment compared to biosimilars. Small molecule generics, which are chemically synthesized compounds with well-defined structures, represent a vast majority of generic medications available worldwide. These drugs typically target a wide range of therapeutic areas, including cardiovascular diseases, central nervous system disorders, and infectious diseases, among others. Small molecule generics are renowned for their cost-effectiveness, accessibility, and therapeutic interchangeability with their brand-name counterparts, making them indispensable components of healthcare systems globally.

Despite the increasing momentum and growing pipeline of biosimilars across therapeutic areas such as oncology, autoimmune diseases, and chronic inflammatory disorders, small molecule generics continue to grow in the Global Generic Drugs Market. This growth can be attributed to several factors, including the established regulatory pathways and approval processes for small molecule generics, which are generally more streamlined compared to biosimilars. Small molecule generics benefit from well-established manufacturing infrastructure, economies of scale, and market familiarity, which contribute to their widespread acceptance and adoption by healthcare providers and patients.

Application Insights

Based on the application segment, cardiovascular diseases stand out as the prominent domain, commanding significant market share and shaping healthcare provision on a global scale. Cardiovascular diseases, encompassing a spectrum of conditions affecting the heart and blood vessels, including hypertension, coronary artery disease, and heart failure, represent a leading cause of morbidity and mortality worldwide. With the increasing prevalence of risk factors such as obesity, sedentary lifestyles, and unhealthy dietary habits, the burden of cardiovascular diseases continues to escalate unabatedly, underscoring the imperative for effective treatment modalities.

Generic drugs play a pivotal role in managing cardiovascular diseases, offering cost-effective alternatives to branded medications such as statins, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors. These medications are widely prescribed for their proven efficacy in reducing cardiovascular events, lowering blood pressure, and improving overall prognosis. The dominance of cardiovascular drugs within the generic drugs market is further amplified by the widespread adoption of preventive strategies and treatment guidelines that emphasize the importance of pharmacological interventions in mitigating cardiovascular risk factors and preventing adverse cardiovascular events.

Regional Insights

North America stands out as a prominent leader in the global generic drugs market, commanding a significant share of market revenue and exerting substantial influence on market trends and innovation. North America's dominance in the global generic drugs market can be attributed to several key factors, including a robust regulatory framework, a well-established healthcare infrastructure, and a highly competitive market landscape. The United States, in particular, represents the largest market for generic drugs globally, driven by factors such as favorable reimbursement policies, patent expirations of branded medications, and widespread acceptance of generic alternatives among healthcare providers and patients alike. The U.S. Food and Drug Administration (FDA) plays a pivotal role in facilitating market access for generic drugs through expedited approval pathways, abbreviated new drug applications (ANDAs), and initiatives aimed at fostering competition and reducing drug costs.

Key Market Players

Teva Pharmaceutical Industries Ltd.

Sandoz International GmbH

Viatris Inc.

Sun Pharmaceutical Industries Ltd.

Fresenius Kabi AG

STADA Arzneimittel AG

Aurobindo Pharma Limited

Dr Reddy's Laboratories Ltd.

Cipla Ltd.

Novo Nordisk A/S

Abbott Laboratories Inc.

Endo International plc

Sanofi S.A.

Aspen Pharmacare Holdings Limited

Lupin Limited

Report Scope:

In this report, the Global Generic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Generic Drugs Market, By Type:

    Small Molecule Generics Biosimilars

Generic Drugs Market, By Application:

    Cardiovascular Diseases Diabetes Neurology Oncology Anti-Inflammatory Diseases Others

Generic Drugs Market, By Drug Delivery:

    Oral Topical Parenteral Others

Generic Drugs Market, By Form:

    Tablet Capsule Injection Others

Generic Drugs Market, By Source:

    In House Contract Manufacturing Organizations

Generic Drugs Market, By Distribution Channel:

    Hospital Pharmacies Retail Pharmacies Online Pharmacies Others

Generic Drugs Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Generic Drugs Market.

Available Customizations:

Global Generic Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Generic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Small Molecule Generics and Biosimilars)
    • 5.2.2. By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others)
    • 5.2.3. By Drug Delivery (Oral, Topical, Parenteral, Others)
    • 5.2.4. By Form (Tablet, Capsule, Injection, Others)
    • 5.2.5. By Source (In House and Contract Manufacturing Organizations)
    • 5.2.6. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 5.2.7. By Region
    • 5.2.8. By Company (2023)
  • 5.3. Market Map

6. North America Generic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Drug Delivery
    • 6.2.4. By Form
    • 6.2.5. By Source
    • 6.2.6. By Distribution Channel
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Generic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Drug Delivery
        • 6.3.1.2.4. By Form
        • 6.3.1.2.5. By Source
        • 6.3.1.2.6. By Distribution Channel
    • 6.3.2. Canada Generic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Drug Delivery
        • 6.3.2.2.4. By Form
        • 6.3.2.2.5. By Source
        • 6.3.2.2.6. By Distribution Channel
    • 6.3.3. Mexico Generic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Drug Delivery
        • 6.3.3.2.4. By Form
        • 6.3.3.2.5. By Source
        • 6.3.3.2.6. By Distribution Channel

7. Europe Generic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Drug Delivery
    • 7.2.4. By Form
    • 7.2.5. By Source
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Generic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Drug Delivery
        • 7.3.1.2.4. By Form
        • 7.3.1.2.5. By Source
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. United Kingdom Generic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Drug Delivery
        • 7.3.2.2.4. By Form
        • 7.3.2.2.5. By Source
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. Italy Generic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Drug Delivery
        • 7.3.3.2.4. By Form
        • 7.3.3.2.5. By Source
        • 7.3.3.2.6. By Distribution Channel
    • 7.3.4. France Generic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Drug Delivery
        • 7.3.4.2.4. By Form
        • 7.3.4.2.5. By Source
        • 7.3.4.2.6. By Distribution Channel
    • 7.3.5. Spain Generic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Drug Delivery
        • 7.3.5.2.4. By Form
        • 7.3.5.2.5. By Source
        • 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Generic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Drug Delivery
    • 8.2.4. By Form
    • 8.2.5. By Source
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Generic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Drug Delivery
        • 8.3.1.2.4. By Form
        • 8.3.1.2.5. By Source
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. India Generic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Drug Delivery
        • 8.3.2.2.4. By Form
        • 8.3.2.2.5. By Source
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. Japan Generic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Drug Delivery
        • 8.3.3.2.4. By Form
        • 8.3.3.2.5. By Source
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. South Korea Generic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Drug Delivery
        • 8.3.4.2.4. By Form
        • 8.3.4.2.5. By Source
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Australia Generic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Drug Delivery
        • 8.3.5.2.4. By Form
        • 8.3.5.2.5. By Source
        • 8.3.5.2.6. By Distribution Channel

9. South America Generic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Drug Delivery
    • 9.2.4. By Form
    • 9.2.5. By Source
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Generic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Drug Delivery
        • 9.3.1.2.4. By Form
        • 9.3.1.2.5. By Source
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. Argentina Generic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Drug Delivery
        • 9.3.2.2.4. By Form
        • 9.3.2.2.5. By Source
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. Colombia Generic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Drug Delivery
        • 9.3.3.2.4. By Form
        • 9.3.3.2.5. By Source
        • 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Generic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Drug Delivery
    • 10.2.4. By Form
    • 10.2.5. By Source
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Generic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Drug Delivery
        • 10.3.1.2.4. By Form
        • 10.3.1.2.5. By Source
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Saudi Arabia Generic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Drug Delivery
        • 10.3.2.2.4. By Form
        • 10.3.2.2.5. By Source
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. UAE Generic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Drug Delivery
        • 10.3.3.2.4. By Form
        • 10.3.3.2.5. By Source
        • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Teva Pharmaceutical Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Sandoz International GmbH
  • 14.3. Viatris Inc.
  • 14.4. Sun Pharmaceutical Industries Ltd.
  • 14.5. Fresenius Kabi AG
  • 14.6. STADA Arzneimittel AG
  • 14.7. Aurobindo Pharma Limited
  • 14.8. Dr Reddy's Laboratories Ltd.
  • 14.9. Cipla Ltd.
  • 14.10. Novo Nordisk A/S
  • 14.11. Abbott Laboratories Inc.
  • 14.12. Endo International plc
  • 14.13. Sanofi S.A.
  • 14.14. Aspen Pharmacare Holdings Limited
  • 14.15. Lupin Limited

15. Strategic Recommendations

16. About Us & Disclaimer